646 related articles for article (PubMed ID: 12562577)
1. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study.
de Haan L; van Bruggen M; Lavalaye J; Booij J; Dingemans PM; Linszen D
Am J Psychiatry; 2003 Feb; 160(2):303-9. PubMed ID: 12562577
[TBL] [Abstract][Full Text] [Related]
2. Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint.
Bernardo M; Parellada E; Lomeña F; Catafau AM; Font M; Gómez JC; López-Carrero C; Gutiérrez F; Pavía J; Salamero M
Psychiatry Res; 2001 Aug; 107(2):87-97. PubMed ID: 11530275
[TBL] [Abstract][Full Text] [Related]
3. Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone.
de Haan L; Lavalaye J; Linszen D; Dingemans PM; Booij J
Am J Psychiatry; 2000 Jun; 157(6):1019-20. PubMed ID: 10831489
[TBL] [Abstract][Full Text] [Related]
4. In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol.
Tauscher J; Küfferle B; Asenbaum S; Fischer P; Pezawas L; Barnas C; Tauscher-Wisniewski S; Brücke T; Kasper S
Psychopharmacology (Berl); 1999 Jan; 141(2):175-81. PubMed ID: 9952042
[TBL] [Abstract][Full Text] [Related]
5. Dosing the antipsychotic medication olanzapine.
Nemeroff CB
J Clin Psychiatry; 1997; 58 Suppl 10():45-9. PubMed ID: 9265916
[TBL] [Abstract][Full Text] [Related]
6. Comparison between olanzapine and haloperidol on procedural learning and the relationship with striatal D2 receptor occupancy in schizophrenia.
Paquet F; Soucy JP; Stip E; Lévesque M; Elie A; Bédard MA
J Neuropsychiatry Clin Neurosci; 2004; 16(1):47-56. PubMed ID: 14990759
[TBL] [Abstract][Full Text] [Related]
7. Treatment response to olanzapine and haloperidol and its association with dopamine D receptor occupancy in first-episode psychosis.
Zipursky RB; Christensen BK; Daskalakis Z; Epstein I; Roy P; Furimsky I; Sanger T; Kapur S
Can J Psychiatry; 2005 Jul; 50(8):462-9. PubMed ID: 16127964
[TBL] [Abstract][Full Text] [Related]
8. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia.
Kapur S; Zipursky R; Jones C; Remington G; Houle S
Am J Psychiatry; 2000 Apr; 157(4):514-20. PubMed ID: 10739409
[TBL] [Abstract][Full Text] [Related]
9. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
Tollefson GD; Beasley CM; Tran PV; Street JS; Krueger JA; Tamura RN; Graffeo KA; Thieme ME
Am J Psychiatry; 1997 Apr; 154(4):457-65. PubMed ID: 9090331
[TBL] [Abstract][Full Text] [Related]
10. Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine--a 123I IBZM single photon emission tomography (SPET) study.
Pilowsky LS; Busatto GF; Taylor M; Costa DC; Sharma T; Sigmundsson T; Ell PJ; Nohria V; Kerwin RW
Psychopharmacology (Berl); 1996 Mar; 124(1-2):148-53. PubMed ID: 8935810
[TBL] [Abstract][Full Text] [Related]
11. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation.
Kapur S; Zipursky RB; Remington G; Jones C; DaSilva J; Wilson AA; Houle S
Am J Psychiatry; 1998 Jul; 155(7):921-8. PubMed ID: 9659858
[TBL] [Abstract][Full Text] [Related]
12. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.
Kapur S; Zipursky RB; Remington G
Am J Psychiatry; 1999 Feb; 156(2):286-93. PubMed ID: 9989565
[TBL] [Abstract][Full Text] [Related]
13. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.
Conley RR; Mahmoud R
Am J Psychiatry; 2001 May; 158(5):765-74. PubMed ID: 11329400
[TBL] [Abstract][Full Text] [Related]
14. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.
Conley RR; Tamminga CA; Bartko JJ; Richardson C; Peszke M; Lingle J; Hegerty J; Love R; Gounaris C; Zaremba S
Am J Psychiatry; 1998 Jul; 155(7):914-20. PubMed ID: 9659857
[TBL] [Abstract][Full Text] [Related]
15. Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia.
Mizrahi R; Rusjan P; Agid O; Graff A; Mamo DC; Zipursky RB; Kapur S
Am J Psychiatry; 2007 Apr; 164(4):630-7. PubMed ID: 17403977
[TBL] [Abstract][Full Text] [Related]
16. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine.
Tollefson GD; Sanger TM
Am J Psychiatry; 1997 Apr; 154(4):466-74. PubMed ID: 9090332
[TBL] [Abstract][Full Text] [Related]
17. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia.
Breier A; Meehan K; Birkett M; David S; Ferchland I; Sutton V; Taylor CC; Palmer R; Dossenbach M; Kiesler G; Brook S; Wright P
Arch Gen Psychiatry; 2002 May; 59(5):441-8. PubMed ID: 11982448
[TBL] [Abstract][Full Text] [Related]
18. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.
Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; Chakos M; McEvoy JP
J Clin Psychiatry; 2002 Oct; 63(10):931-5. PubMed ID: 12416603
[TBL] [Abstract][Full Text] [Related]
19. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate.
Nyberg S; Farde L; Halldin C; Dahl ML; Bertilsson L
Am J Psychiatry; 1995 Feb; 152(2):173-8. PubMed ID: 7840348
[TBL] [Abstract][Full Text] [Related]
20. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia.
Wright P; Birkett M; David SR; Meehan K; Ferchland I; Alaka KJ; Saunders JC; Krueger J; Bradley P; San L; Bernardo M; Reinstein M; Breier A
Am J Psychiatry; 2001 Jul; 158(7):1149-51. PubMed ID: 11431240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
